Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) shares shot up 2.4% on Thursday . The company traded as high as $17.53 and last traded at $17.25. 128,315 shares changed hands during mid-day trading, an increase of 156% from the average session volume of 50,104 shares. The stock had previously closed at $16.85.
Neoleukin Therapeutics Price Performance
The stock’s 50 day simple moving average is $20.14 and its two-hundred day simple moving average is $17.53. The stock has a market cap of $162.12 million, a P/E ratio of -5.55 and a beta of 1.11.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Further Reading
- Five stocks we like better than Neoleukin Therapeutics
- What is Forex and How Does it Work?
- Lower Rates Put RV Stocks Back in the Fast Lane
- Insider Trades May Not Tell You What You Think
- Alphabet: Time to Take Profits, Buy, or Wait for a Pullback?
- Best Aerospace Stocks Investing
- Hershey vs. Mondelez: Which Stock Wins Chocolate Season?
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
